Company Overview

Cerimon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics in the areas of autoimmune disease, inflammation and pain. The Company currently has two drugs in development, a topical patch formulation of diclofenac sodium for the treatment of musculoskeletal pain and Simulect® (basiliximab) for the treatment of moderate-to-severe, steroid-refractory ulcerative colitis.

The Company's name is derived from a character in Shakespeare's play Pericles. Cerimon was a kindly physician who miraculously healed his patients. The Cerimon name symbolizes the Company's desire to provide patients with therapeutics that address today's unmet medical needs.

Cerimon has built an exceptionally experienced management team with a solid track record. The Company’s team members have played key roles in the successful development and commercialization of over 40 products, including Valcyte, Roferon, Aleve and CellCept, and have managed the sales and/or marketing activities for some of the world's top-selling drugs, including Norvasc, Lipitor, Viagra, Glucotrol XL, Rituxan, Gonal-f®, Duragesic, Zestril and Nolvadex.

Cerimon is well financed, having secured a $70 million Series A financing in late 2005 with investors MPM, Nomura Phase4 Ventures and OrbiMed Advisors.